Good news: Mobosetinib/Mobosetinib is already on the market in China

As ofFebruary 2024, Mobocertinib/Mobocertinib (Mobocertinib)The original drug has been launched in China and can treat patients with /span>Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations(NSCLC) whose disease has progressed during or after platinum-based chemotherapy.

Mobosetinib was reviewed as part of the National Medical Products Administration's Breakthrough Therapy Program, and therefore full approval of the oral TKI may depend on verification of clinical benefit in confirmatory trials. However, with this decision, mobosetinib became the first and only available treatment for this population in China. Lung cancer is a devastating disease, and we know that discovering and delivering precision medicines that target hard-to-treat cancer types, such as moboxetinib, has the potential to improve patient outcomes, leading to an independent review committee (IRC) assessment of a confirmed ORR of 28% in this patient population. Additionally, the drug's median DOR was 15.8 months. The median progression-free survival and overall survival of TKI patients were 7.3 months and 20.2 months, respectively.

The domestically marketed original drug Mobosetinib has not been included in medical insurance due to its short time on the market. The price of the common specification 40mg*112 pills per box is around 40,000 yuan, which is very high. The price of the Hong Kong clinical version 40mg*30 pills per box is over 7,000 yuan (the price may fluctuate due to the exchange rate). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.